Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2016

Primary Completion Date

November 30, 2019

Study Completion Date

April 30, 2020

Conditions
Carcinoma, Non-Small-Cell LungNon-Small Cell Lung CancerNonsmall Cell Lung Cancer
Interventions
DRUG

Rociletinib

PROCEDURE

Biopsy

Standard of care biopsies will be taken at diagnosis and at the time of disease progression

PROCEDURE

Blood draw

-Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT02705339 - Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter